{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:55:41Z","timestamp":1791341741829,"version":"4.3.1"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CLIN INFECT DIS"],"published-print":{"date-parts":[[2003,2,15]]},"DOI":"10.1086\/367662","type":"journal-article","created":{"date-parts":[[2003,7,23]],"date-time":"2003-07-23T20:31:43Z","timestamp":1058992303000},"page":"473-481","source":"Crossref","is-referenced-by-count":134,"title":["Quinupristin\u2010Dalfopristin and Linezolid: Evidence and Opinion"],"prefix":"10.1093","volume":"36","author":[{"given":"George M.","family":"Eliopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"rf1_383","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)80002-3"},{"key":"rf2_384","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00334-0"},{"key":"rf3_385","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.593"},{"key":"rf4_386","first-page":"565","volume":"51","author":"Centers","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"rf5_387","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.7"},{"key":"rf6_388","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(97)00464-2"},{"key":"rf7_389","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.171"},{"key":"rf8_390","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2200-2207.2002"},{"key":"rf9_391","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002."},{"key":"rf10_392","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00129-0"},{"key":"rf11_393","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00234-0"},{"key":"rf12_394","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/JCM.38.8.2819-2823.2000","volume":"38","author":"von Eiff C","year":"2000","journal-title":"J Clin Microbiol"},{"key":"rf13_395","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00123-1"},{"key":"rf14_396","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00147-3"},{"key":"rf15_397","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.5.689"},{"key":"rf16_398","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.6.847"},{"key":"rf17_399","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.931"},{"key":"rf18_400","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00371-1"},{"key":"rf19_401","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.6.783"},{"key":"rf20_402","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.10.3586-3590.2001"},{"key":"rf21_403","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00121-7"},{"key":"rf22_404","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00374-7"},{"key":"rf23_405","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1128\/JCM.37.6.1876-1880.1999","volume":"37","author":"Wisplinghoff H","year":"1999","journal-title":"J Clin Microbiol"},{"key":"rf24_406","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.5.1928-1931.2001"},{"key":"rf25_407","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00111-5"},{"key":"rf26_408","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1845-1850.2002"},{"key":"rf27_409","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.42.5.1088","volume":"42","author":"Eliopoulos GM","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"rf28_410","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3374-3380.2000"},{"key":"rf29_411","first-page":"401","volume":"17","author":"Werner G","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"rf30_412","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2931-2932.2001"},{"key":"rf31_413","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2298-2299.2001"},{"key":"rf32_414","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010805"},{"key":"rf33_415","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(95)00068-L"},{"key":"rf34_416","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf080"},{"key":"rf35_417","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.41.12.2749","volume":"41","author":"Caron F","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"rf36_418","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.467"},{"key":"rf37_419","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2880-2882.2000"},{"key":"rf38_420","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.115"},{"key":"rf39_421","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2174-2178.2002"},{"key":"rf40_422","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.775"},{"key":"rf41_423","first-page":"227","volume":"21","author":"Batts DH","year":"2001","journal-title":"Curr Clin Top Infect Dis"},{"key":"rf42_424","doi-asserted-by":"publisher","DOI":"10.1086\/313766"},{"key":"rf43_425","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.251"},{"key":"rf44_426","doi-asserted-by":"publisher","DOI":"10.1086\/323899"},{"key":"rf45_427","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.263"},{"key":"rf46_428","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/ajrccm.161.3.9904115","volume":"161","author":"Fagon JY","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"rf47_429","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.1.105"},{"key":"rf48_430","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00154-6"},{"key":"rf49_431","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/clinids\/24.1.91","volume":"24","author":"Chow JW","year":"1997","journal-title":"Clin Infect Dis"},{"key":"rf50_432","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_1.37"},{"key":"rf51_433","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0665"},{"key":"rf52_434","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(01)00180-9"},{"key":"rf53_435","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3202-3204.2001"},{"key":"rf54_436","doi-asserted-by":"publisher","DOI":"10.1086\/318702"},{"key":"rf55_437","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-133-6-200009190-00029","volume":"133","author":"Cole RP","year":"2000","journal-title":"Ann Intern Med"},{"key":"rf56_438","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1086\/516890","volume":"25","author":"Launay O","year":"1997","journal-title":"Clin Infect Dis"},{"key":"rf57_439","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.639"},{"key":"rf58_440","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1080-1085.2002"},{"key":"rf59_441","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-001-0023-7"},{"key":"rf60_442","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.6.797"},{"key":"rf61_443","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2154-2156.2001"},{"key":"rf62_444","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00333-9"},{"key":"rf63_445","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04376-2"},{"key":"rf64_446","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200203143461121"},{"key":"rf65_447","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"rf66_448","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.1.77"},{"key":"rf67_449","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.40.7.1745","volume":"40","author":"Eliopoulos GM","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"rf68_450","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00210-1"},{"key":"rf69_451","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00071-0"},{"key":"rf70_452","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3408-3413.2000"},{"key":"rf71_453","doi-asserted-by":"publisher","DOI":"10.1086\/318486"},{"key":"rf72_454","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"key":"rf73_455","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10062"},{"key":"rf74_456","doi-asserted-by":"publisher","DOI":"10.1086\/340265"},{"key":"rf75_457","doi-asserted-by":"crossref","unstructured":"Bassetti M, DiBiagio A, Cenderello G, etal Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA) J Infect 2001; 43:148-57.","DOI":"10.1053\/jinf.2001.0863"},{"key":"rf76_458","doi-asserted-by":"publisher","DOI":"10.1086\/313597"},{"key":"rf77_459","doi-asserted-by":"publisher","DOI":"10.1086\/319986"},{"key":"rf78_460","doi-asserted-by":"publisher","DOI":"10.1086\/313669"},{"key":"rf79_461","unstructured":"Moise PA, Birmingham MC, Forrest A, Schentag JJ. Linezolid use in patients who are intolerant to or fail vancomycin [abstract 2233]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000."},{"key":"rf80_462","unstructured":"Dresser LD, Birmingham MC, Karchmer AW, etal Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000."},{"key":"rf81_463","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf066"},{"key":"rf82_464","doi-asserted-by":"publisher","DOI":"10.1007\/s100960100512"},{"key":"rf83_465","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200112000-00023"},{"key":"rf84_466","doi-asserted-by":"publisher","DOI":"10.1086\/321896"},{"key":"rf85_467","unstructured":"Sperber SJ, Levine JF, Gross PA. Low serum linezolid levels in a patient with persistent MRSA bacteremia [abstract 465]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001."},{"key":"rf86_468","unstructured":"Brown-Elliott BA, Wallace RJ Jr, Griffith DE, etal Safety and tolerance of long-term therapy of linezolid for mycobacterial and nocardial disease with a focus on once daily therapy [abstract 609]. In: Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002."},{"key":"rf87_469","doi-asserted-by":"publisher","DOI":"10.1086\/340710"},{"key":"rf88_470","unstructured":"Hicks K, Hachem RY, Huen A, Raad II. Myelosuppression and serotonin syndrome associated with linezolid and selective serotonin re-uptake inhibitors (SSRIs) [abstract 467]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001."},{"key":"rf89_471","unstructured":"88A Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn, 2002."},{"key":"rf90_472","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2723-2726.2002"},{"key":"rf91_473","doi-asserted-by":"publisher","DOI":"10.1086\/341310"},{"key":"rf92_474","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"key":"rf93_475","unstructured":"Forrest A, Rayner CR, Meagher A, etal Pharmacostatistical modelling of hematologic effects of linezolid in seriously ill patients [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000."},{"key":"rf94_476","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.10.1291"},{"key":"rf95_477","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.16.1973"},{"key":"rf96_478","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.16.1974"},{"key":"rf97_479","doi-asserted-by":"publisher","DOI":"10.1086\/340982"},{"key":"rf98_480","doi-asserted-by":"publisher","DOI":"10.1086\/341309"},{"key":"rf99_481","unstructured":"Patron RL. Myelodisplasia and severe fatal pancytopenia associated with linezolid treatment [abstract 466]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001."},{"key":"rf100_482","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110077245"},{"key":"rf101_483","unstructured":"Moise-Broder PA, Forrest A, Jagodzinski LM, Schentag JJ. Methicillin-resistant Staphylococcus aureus bloodstream infections failing vancomycin (Vm): results of increasing Vm versus adding quinupristin-dalfopristin to Vm [abstract 182]. In: Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/36\/4\/473\/1208367\/36-4-473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T20:27:52Z","timestamp":1585081672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/367662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,15]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,2,15]]}},"alternative-id":["10.1086\/367662"],"URL":"https:\/\/doi.org\/10.1086\/367662","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,15]]}}}